Drug intelligence / Profile preview

boldenone

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Intramuscular
01

Overview

Boldenone is a synthetic anabolic–androgenic steroid (AAS) and a derivative of testosterone developed primarily for veterinary use, especially in horses[1][2][3]. It is not approved for human use in the United States or most other countries. Boldenone acts as an agonist of the androgen receptor and exerts its effects by regulating gene transcription after binding to this receptor[1][3]. Its activity is mainly anabolic with relatively low androgenic potency. The drug increases nitrogen retention and protein synthesis, stimulates appetite, and promotes erythropoietin release from the kidneys[2][3]. While originally developed for medical purposes (with early clinical formulations such as Parenabol), it was discontinued for human use due to lack of therapeutic benefit and potential side effects. Currently, boldenone undecylenate (a long-lasting ester form) remains available under brand names like Equipoise for veterinary applications but is also misused illicitly by athletes seeking performance enhancement[5].

Brand names
EquipoiseParenabol
Other names
Δ1-testosterone1-dehydrotestosteroneandrosta-1,4-dien-17β-ol-3-one
02

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on boldenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on boldenone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call